医疗健康公司雅培亮相第七届中国国际进口博览会。在医疗器械及医药保健展区打造的创意健康空间中,雅培全方位展现涵盖诊断、医疗器械、营养品和药品等领域的前沿科技和创新成果。据悉,雅培国产免疫模块Alinity i和自动化流水线GLP已正式上市,其将助力“中国智造”的创新诊疗资源覆盖更多地区。
作为全球医疗健康领域的创新者,雅培通过进博会展示的数百款创新生命科技中已有不少陆续落地中国市场,从展品变为中国大众用得好的医疗健康产品。其中,于第五届进博会“首秀”的AVEIRTM VR单腔植入式无导线心脏起搏器现已在中国正式获批上市,为心动过缓的患者带来了全新的治疗选择;全球首个获批且目前唯一同时获得国家药品监督管理局、欧盟CE、美国食品药品监督管理局三大权威认证的HeartMate 3植入式左心室辅助系统也获批上市并于近日迎来首批植入,为中国晚期心力衰竭患者提供新治疗选择,提高存活率和生活质量。
雅培核心诊断业务全球副总裁陈迎表示:作为绝佳互动交流平台,进博会能够助力企业与政府以及众多行业伙伴不断探索合作新机会。很高兴继续通过进博会向大家全面展示创新成果并且见证这些健康解决方案覆盖更广泛的地区,助力更多人过上更美好的生活。
(文章来源:广州日报)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.